DelveInsight's 'HR Positive her2 Negative Breast Cancer Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of HR-positive/HER2-negative breast cancer from 2017 to 2028 segmented by the seven major markets.
HR Positive her2 Negative breast cancer is the most common form of breast cancer. This type accounts for a higher percentage of all breast cancers. Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Addition to this, there is another factor which is also responsible for breast cancer which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. There are more number of cases for breast cancer in women observed in comparison to the men.
HR-positive cancer is usually treated with Endocrine therapies or a combination of hormone therapy with targeted therapy to help stop tumor growth first. However, sometimes cancer outsmarts the treatment and becomes resistant to hormonal therapy and stops working. Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects depending on the tissue, cell or promoter.
Currently there are number of classes of anti-estrogenic agents available for patients with early, advanced, or metastatic breast cancer which includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.
ETs are a common first-line treatment in advanced or metastatic breast cancer (MBC), resistance inevitably develops. Some patients may develop resistance to ET with one agent class, a response to treatment may occur with exposure to another class. Sequential ET is preferred in postmenopausal women with HR+, HER2- MBC. Guidelines currently recommend Aromatase Inhibitors (AIs) with the CDK4/6 inhibitors, palbociclib or ribociclib, or fulvestrant as a first-line ET option. As a second-line ET option, fulvestrant in combination with palbociclib or abemaciclib is recommended for patients with prior adjuvant ET exposure or patients who received ET in the metastatic setting. However there is one drawback of Endocrine therapies that patients become resistance to this after continues use. For this Targeted CDK4/6 Inhibitors are used as First-Line Regimens. In addition to this, First-Line Regimens, mTOR Inhibitors and Akt Inhibitors also recommended.
The DelveInsight's HR Positive her2 Negative Breast Cancer market report gives a thorough understanding of the HR-positive/HER2-negative by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HR-positive/HER2-negative in the US, Europe, and Japan
Comments
Post a Comment